A groundbreaking study reveals that scientists have discovered a method to reprogram the pancreas to produce GLP-1s naturally, eliminating the need for Ozempic and offering new hope for sustainable weight loss.
In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
In a groundbreaking move, President Trump has negotiated significant price reductions for popular weight loss medications, bringing costs down to as low as $50 per month for eligible patients. Find out how these changes will affect access to essential treatments!
In a groundbreaking move, President Trump announces deals with Eli Lilly and Novo Nordisk to reduce obesity drug prices, making treatments more accessible for millions of Americans. Medicare coverage for GLP-1 drugs starts in 2026, changing the landscape of obesity treatment.
Two biotech companies are developing groundbreaking gene therapies that could lead to a single injection for weight loss and blood sugar control. Initial tests show promising results in mice, with human trials on the horizon.
As demand for weight loss and diabetes drugs surges, Eli Lilly and Novo Nordisk dominate the market. Discover the challenges, competition, and future of this booming industry.
Young Russians are flocking to a cheap weight-loss pill called Molecule, lured by TikTok trends. But behind the promise of rapid weight loss lies a dangerous substance linked to severe health risks and hospitalizations.
Eli Lilly's third-quarter results exceeded estimates, driven by strong demand for Zepbound and Mounjaro. The company raised its revenue forecast, fueling a 5% rise in shares. Discover how Eli Lilly is maintaining its lead in the competitive obesity drug market.
A new report reveals that the U.S. adult obesity rate has declined to 37% in 2025, down from a record 39.9% in 2022, as more Americans turn to weight loss drugs like GLP-1 injectables. With 7.6 million fewer obese adults, is this the start of a healthier trend?
A recent Gallup survey reveals a rapid increase in the use of injectable obesity treatments, correlating with a drop in obesity rates among U.S. adults. Discover the implications and future of these groundbreaking medications!